International Medical Cannabis Conference
13. bis 14. Februar
Universität Bern
Von Roll Campus
Fabrikstrasse 6
3012 Bern
Schweiz
Die International Medical Cannabis Conference (IMCCB) der Universität Bern ist eine der größten Medizinalcannabis-Konferenzen Europas.
Der Kongress, der in englischer Sprache stattfindet, legt seinen Fokus auf neueste Erkenntnis aus der Medizin. Die zweitägige Veranstaltung umfasst unter anderem verschiedene Panels, Diskussionspodien, Vorträge, eine Ausstellung und mehr. Hier geht es zur Liste der Referentinnen und Referenten.
Aufbauend auf dem Erfolg früherer Schweizer Cannabiskongresse strebt die IMCCB-25 danach, eine vielfältige Versammlung von führenden Forschern, Klinikern, Industriefachleuten und anderen Experten und Meinungsführern aus der ganzen Welt zusammenzubringen. Tauchen Sie mit uns ein in die neuesten Erkenntnisse über klinische Evidenzen und Innovationen bei der Behandlung mit medizinischem Cannabis. Nehmen Sie teil an den kritischen Diskussionen von internationalen Experten über die Herausforderungen der evidenzbasierten Medizin und Cannabiskonsumstörungen.
Eine Anmeldung ist über diesen Weblink möglich.
Programm
Thursday 13 February
8.00 Registration / Welcome Coffee
9.00-9.15 Opening and Welcome Addresses
Jürg Gertsch & Rudolf Brenneisen, Conference Chairs
Representative of Rectorate University of Bern
Petra Baeriswy, Swiss Federal Office of Public Health
9.15-10.45 Session 1 Endocannabinoid System and Pharmacology (Chair Jürg Gertsch)
L-1 The Day Anandamide Almost Died and Other Endocannabinoid Stories
Daniele Piomelli, University of California Irvine, USA
L-2 Endocannabinoidome Signaling: From Gut to Brain and Across Different Kingdoms, and Intersections with Plant Cannabinoids
Vincenzo di Marzo, Université Laval, Quebec, Canada & Institute of Biomolecular Chemistry, C.N.R. Italy
L-3 Cannabinoid and Stress – Mechanistic Aspects
Beat Lutz, University of Mainz, Germany
10.45-11.45 Coffee Break, Poster Viewing, Visit the Exhibition, Networking
11.45-13.00 Session 2 From Cannabis to Effects and Medicines (Chair Matthias Hamburger)
L-4 50 Years of Phytochemistry and Analytics
Mahmoud ElSohly, University of Mississippi, Oxford, USA
L-5 Personalized Cannabis Medicines – What is the Evidence?
Guillermo Moreno-Sanz, Khiron Europe, Spain
L-6 Sites and Mechanisms Underlying Cannabinoid-Induced Antinociception
David Finn, University of Galway, Ireland
13.00-13.30 Panel 1
L-1 to L-6 Ask the experts – panel discussion (Chairs Jürg Gertsch & Matthias Hamburger)
13.30-14.30 Lunch Break, Poster Viewing, Visit the Exhibition, Networking
14.30-15.30 Session 3 Cannabis-based Medicines (CBMs) in a Clinical Setting (Chair Reto Agosti)
L-7 CBMs in Pain Disorders – What is the Evidence?
Matthias Karst, Hannover Medical School, Germany
L-8 Cannabinoids for Neurodegeneration – Fact or Fiction?
Markus Weber, Cantonal Hospital St. Gallen, Switzerland
L-9 CBMs in Psychiatric and Substance Use Disorders
Patrik Roser, University Hospital of Psychiatry Zürich, Switzerland
15.30-16.30 Session 4 Cannabinoids Between Research and Therapeutic Applications (Chair Rudolf Brenneisen)
L-10 Cannabinoid-based Therapies for Treating Metabolic Diseases
Yossi Tam, The Hebrew University of Jerusalem, Israel
L-11 The Value of Real-World Evidence in Cannabis Therapies
Anne Katrin Schlag, Drug Science & Imperial College London, UK
L-12 The Use of Tetrahydrocannabinol in Palliative Cancer Patients
Thomas Herdegen, University Clinics of Kiel, Germany
16.30-17.00 Panel 2
L-7 to L-12 Ask the experts – panel discussion (Chairs Reto Agosti & Rudolf Brenneisen)
17.00-18.00 Coffee Break, Poster Viewing, Visit the Exhibition, Networking
18.00-19.00 Session 5 Towards Evidence-Based Cannabis Medicines, Opportunities and Risks I (Chair Claude Vaney)
L-13 CBMs in Sleep Disorders
Kirsten Müller-Vahl, Medizinische Hochschule Hannover, Germany
L-14 Medical Cannabis for Behavioral Symptoms in Patients with Severe Dementia: The MedCanDem Study
Federica Bianchi, Geneva University Hospital, Switzerland
L-15 Cannabis in Pain Treatment : The Challenge between Science and Clinical Evidence
Thomas R. Tölle, Technische Universität München, Germany
19.00-19.30 Panel 3
L-13 to L-15 Ask the experts – panel discussion (Chair Claude Vaney)
19.30 APÉRO RICHE
Friday 14 February
8.30 Registration / Welcome Coffee
9.00-10.00 Session 6 Towards Evidence-Based Cannabis Medicines, Opportunities and Risks II (Chair Simon Nicolussi)
L-16 Cannabinoid Drug-Drug Interactions
Kent E. Vrana, Pennsylvania State University College of Medicine, Hershey, USA
L-17 Risks of Cannabis-based Medicine
Margaret Haney, Columbia University Medical Center, New York, USA
L-18 Challenges and Opportunities of Cannabis e-Cigarettes (e-Joints)
Reto Auer, University of Bern, Switzerland
10.00-10.30 Panel 4
L-16 to L-18 Ask the experts – panel discussion (Chair Simon Nicolussi)
10.30-11.00 Coffee Break, Poster Viewing, Visit the Exhibition, Networking
11.00-12.30 Session 7 Short Presentations of Various Topics (Chair Federica Bianchi)
L-19 SOP I: MEMORY & Research within the Florida Medical Marijuana Consortium
Almut Winterstein, University of Florida, Gainesville, USA
L-20 SOP II: tba
L-21 SOP III: tba
L-22 SOP IV: tba
L-23 SOP V: tba
12.30-13.00 Panel 5
L-19 to L-23 Ask the experts – panel discussion (Chairs Federica Bianchi)
13.00-14.00 Lunch Break, Poster Viewing, Visit the Exhibition, Networking
14.00-16.00 Session 8 Monitoring Real-World CBM Applications and Country Reports (Chair Aleksandra Kupferberg)
L-24 PEP: Leveraging Real-World Evidence for Advancing Cannabis-Based Medicinal Product Therapies
Garvin Hirt, Copeia GmbH, Bergisch Gladbach, Germany
L-25 Reporting System MeCanna –Features, Challenges and Opportunities
Christian Werz, Federal Office of Public Health, Switzerland
L-26 Country Report USA: Evidence Review Supporting United States Policy Change
Amie Goodin, University of Florida, Gainesville, USA
L-27 Country Report: Germany
Konrad F. Cimander, Wedemark, Germany
L-28 Country Report: Spain
Guillermo Moreno-Sanz, Khiron Europe, Spain
L-29 Medical Cannabis Regulation in Latin America: A Comparative Analysis
Sandra Carillo, Colombian Medical Association of Cannabinoid Medicines, Medellin, Colombia
16.00-16.30 Panel 6
L-24 to L-29 Ask the experts – panel discussion (Chair Aleksandra Kupferberg)
16.30-17.00 Coffee Break, Poster Viewing, Visit the Exhibition, Networking
17.00-18.00 Session 9 The Journey from Non-Medical to Evidence-Based Medical Cannabis (Chair Thomas Herdegen)
L-30 Questioned Evidence: Effectiveness and Harms in RCTs and Beyond
John Ioannidis, Stanford University, USA
L-31 Non-medical Cannabis Use: First Results from a Swiss Pilot Trial (Cann-L)
Frank Zobel, Addiction Switzerland, Lausanne, Switzerland
L-32 Hot Topics in Cannabis Research
Jürg Gertsch, University of Bern, Switzerland
18.00-18.30 Panel 7
L-24 to L-29 Ask the experts – panel discussion (Chairs Thomas Herdegen, tba)
18.30 Awards & Closing Remarks
Jürg Gertsch & Rudolf Brenneisen